1. Pink Sheet
  2. >>Geography
  3. >>Europe

Brexit: Scenario Planning Well Under Way At EMA

 
• By Ian Schofield

The EMA has outlined some of the planning that has been going on in preparation for its relocation from the UK to another EU member state as a result of Brexit, including ongoing relations with the UK regulator, the MHRA.

EMA offices
The EMA has been looking at the impact on regulation of its move from London

In the nine months since the UK voted to leave the EU, the European Medicines Agency has been working out how best to deal with two key issues: whether, and how, the UK regulator, the MHRA, might continue to work with or within the EU drug regulatory system, and the challenges posed by the EMA’s forced relocation to one of the remaining 27 EU member states.

The EMA’s planning has been underpinned by the establishment of an Operational Relocation Preparedness (ORP) task force at the EMA,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 
• By Eliza Slawther

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions

 
• By Sarah Karlin-Smith

In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.

33 States Agree To Standardized Access Policies In Medicaid Sickle Cell Payment Demo

 
• By Alaric DeArment and Cathy Kelly

States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.